Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Pharmacokinetics analysis of novel candidate drugs against hepatic B virus

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: HASHIMOTO, Mai (Sojo University, Faculty of Pharmaceutical Sciences, Kumamoto, Japan)
  • Co-author(s): Mai Hashimoto: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
    Kazuaki Taguchi: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
    Takako Ishiguro: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan
    Keishi Yamasaki: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan;DDS Research Institutes, Sojo University, Kumamoto, Japan
    Satoru Kohgo: Research Institute & Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
    Hiroaki Mitsuya: Research Institute & Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan;National Cancer Institute, National Institutes of Health, Bethesda, MD, United States;Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
    Masaki Otagiri: Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan;DDS Research Institutes, Sojo University, Kumamoto, Japan
  • Abstract:

    Backgrounds

    Although a few drug against hepatitis B virus (HBV) are approved and used in clinics all over the world, there are some limitations to completely treat HBV because of the appearance of drug-resistance HBV. To overcome this issue, it is desirable to develop novel drugs against drug-resistance HBV. Our group have developed..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses